Swisslog Healthcare Unveils New Complementary Features for AutoPack Automated Oral Solid Packager
BROOMFIELD, Colo.--(BUSINESS WIRE)-- Swisslog Healthcare, a leader in pharmacy and transport automation solutions, introduces new complementary features for the AutoPack™ Automated Oral Solid Packager. The U-Canister and Variable Heater enhance the AutoPack's efficiency in hospital pharmacies, freeing up pharmacists for more patient-centric care.
The AutoPack, an automated oral solid packager, addresses several key challenges faced by hospital pharmacies. AutoPack supports up to 480 medications in a single packager. It can operate with or without hospital information system integration, enabling pharmacies to pre-package tablets for unit dose dispense or fill orders on demand. The new complementary features support the automation abilities of the AutoPack.
"These new features upgrade the AutoPack, creating a more comprehensive packaging solution to improve efficiency and address critical workforce shortages in hospital pharmacies," said Connie Vigil, Business Analyst at Swisslog Healthcare. "These pharmacy automation additions save time, reduce costs, and improve organization and accuracy in medication management."
The U-Canister accommodates up to 280 tablets, including halved tablets and those with special shapes, benefiting long-term patients with complex medication regimens. Its larger internal chute allows for packaging of bigger tablets, while preventing more than one tablet from being packaged at a time. The U-Canister also features a swappable internal cup, simplifying the process of changing dispensed tablets. This design enables the packaging of tablets not already stored within an AutoPack canister, increasing flexibility in medication management.
The Variable Heater, now standard with all AutoPack units, allows technicians to customize output package sizes to meet desired lengths. Available package lengths include 50 mm, 56 mm, 65 mm, 75 mm, 85 mm, and 95 mm. Decreased package sizes facilitate easier integration with cartfill/ADU workflows, boosting overall pharmacy efficiency.
AutoPack comes in two styles with nine capacity options, ranging from 244-480 canisters, to fit various pharmacy needs. Its design allows for easy replacement of the main frame packaging unit, reducing downtime and boosting productivity. The packager includes a standard Special Tablet System (STS) Tray and AutoCanisters™, which handle half tablets, infrequently used tablets, and tablets with special shapes.
The added AutoPack features are now available for hospitals across North America. More information can be found at https://www.swisslog-healthcare.com/en-us/products/pharmacy-automation/autopack-automated-oral-solid-packager.
About Swisslog Healthcare:
Swisslog Healthcare provides pharmacy workflow automations through robotic solutions and operational technology that enable hospitals and health systems to assist providers in treating patients across the continuum of care. Integrating transport and pharmacy automation, value-added services, and intelligent software, Swisslog Healthcare enables healthcare providers to respond to patients' needs quickly and with greater accuracy. The company minimizes many sources of operational waste, so providers achieve higher levels of productivity to impact the well-being of patients in positive ways. For more information, visit www.swisslog-healthcare.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Destiny Tech100 Inc. Reports First Quarter 2025 Results
NEW YORK, June 13, 2025--(BUSINESS WIRE)--Destiny Tech100 Inc. (NYSE: DXYZ) today announced financial results for the quarter ended March 31, 2025. The fund reported a net asset value (NAV) of $6.31 per share of common stock, from $6.44 per share at the end of the fourth quarter of 2024. As of March 31, 2025, Destiny Tech100's investment portfolio had an aggregate fair value of approximately $69.6 million, including short-term investments. The fund maintains positions in a variety of privately-held technology companies. Additional Information For more information about the Tech100 fund, Destiny XYZ Inc., the Fund's parent company, has made extensive resources available on its website. Prospective investors and the general public are encouraged to visit (in the Literature section) to receive the Fund's most recent annual report and other important information. About Destiny Tech100 Destiny Tech100 ("DXYZ" and "Tech100"), is a publicly-listed registered closed-end fund that intends to invest in a portfolio of 100 of the top venture-backed private technology companies, providing everyday investors access to many of the world's most exciting private businesses. Destiny Tech100 Inc. is currently listed on the New York Stock Exchange under the ticker symbol "DXYZ." For a comprehensive list of holdings, visit the fund website at View source version on Contacts Robert Blecherpress@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Destiny Tech100 Inc. Reports First Quarter 2025 Results
NEW YORK, June 13, 2025--(BUSINESS WIRE)--Destiny Tech100 Inc. (NYSE: DXYZ) today announced financial results for the quarter ended March 31, 2025. The fund reported a net asset value (NAV) of $6.31 per share of common stock, from $6.44 per share at the end of the fourth quarter of 2024. As of March 31, 2025, Destiny Tech100's investment portfolio had an aggregate fair value of approximately $69.6 million, including short-term investments. The fund maintains positions in a variety of privately-held technology companies. Additional Information For more information about the Tech100 fund, Destiny XYZ Inc., the Fund's parent company, has made extensive resources available on its website. Prospective investors and the general public are encouraged to visit (in the Literature section) to receive the Fund's most recent annual report and other important information. About Destiny Tech100 Destiny Tech100 ("DXYZ" and "Tech100"), is a publicly-listed registered closed-end fund that intends to invest in a portfolio of 100 of the top venture-backed private technology companies, providing everyday investors access to many of the world's most exciting private businesses. Destiny Tech100 Inc. is currently listed on the New York Stock Exchange under the ticker symbol "DXYZ." For a comprehensive list of holdings, visit the fund website at View source version on Contacts Robert Blecherpress@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
